KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) EBITDA Margin (2019 - 2025)

Esperion Therapeutics (ESPR) has disclosed EBITDA Margin for 7 consecutive years, with 36.71% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 6755.0% year-over-year to 36.71%, compared with a TTM value of 5.63% through Dec 2025, up 994.0%, and an annual FY2025 reading of 5.63%, up 994.0% over the prior year.
  • EBITDA Margin was 36.71% for Q4 2025 at Esperion Therapeutics, up from 35.89% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 44.3% in Q1 2024 and bottomed at 1139.82% in Q1 2021.
  • Average EBITDA Margin over 5 years is 216.9%, with a median of 148.07% recorded in 2023.
  • The sharpest move saw EBITDA Margin surged 311360bps in 2021, then plummeted -24480bps in 2022.
  • Year by year, EBITDA Margin stood at 423.02% in 2021, then surged by 30bps to 294.38% in 2022, then skyrocketed by 41bps to 174.71% in 2023, then skyrocketed by 82bps to 30.85% in 2024, then soared by 219bps to 36.71% in 2025.
  • Business Quant data shows EBITDA Margin for ESPR at 36.71% in Q4 2025, 35.89% in Q3 2025, and 15.45% in Q2 2025.